Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Data Center Outlook for the European Market

To get a perspective on how the data center industry is faring in European markets during the pandemic, host Raymond Hawkins tapped Andrew Jay, Head of EMEA Data Centre Solutions, Advisory & Transaction Services for CBRE, to help him unpack what’s happening. The need for co-location space is growing in Europe, as demands for data…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
The Data Center Outlook for the European Market

To get a perspective on how the data center industry is faring in European markets during the pandemic, host Raymond Hawkins tapped Andrew Jay, Head of EMEA Data Centre Solutions, Advisory & Transaction Services for CBRE, to help him unpack what’s happening.

The need for co-location space is growing in Europe, as demands for data storage are at unprecedented levels and have been for several years.

London is one of the largest areas of need, and Jay said, “There’s an absolute feeding frenzy at the moment of developer operators trying to secure land. And then there are the usual issues around power, planning, fiber and risks. The prices of these sites are going through the roof at the moment.”

Due to the lack of real estate around London and the high demand, there is intense competition for sites. And Jay said he’s seen deals around London going north of six million pounds per acre.

With London pricing many out of the market, what’s the next area of opportunity for data centers? Jay said North London, where there’s a lot of land interest.

“What we haven’t seen is East London yet, and we have a couple of really good quality data center builds there, but the demand hasn’t quite got there yet,” he said.

As for the state of data centers in other European markets, Jay cited Milan as an example.

“For years, there was no demand there. Suddenly, about three to four years ago, we got calls from people asking if we had any land available in Milan,” he said. “So, that market’s gone from being a 15-megawatt to a 60-65-megawatt market.” And Jay believes that could easily double shortly.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512